SCHEMBL4304707

SCHEMBL4304707

O=C(OC(Cn1ncnn1)c1ccccc1Cl)N1CCN(c2ccccc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.40
POLB P06746 2/20 0.39
DGAT1 O75907 3/20 0.39
MEN1 O00255 2/20 0.37
FAAH O00519 1/20 0.37
MGLL Q99685 1/20 0.37
GFER P55789 1/20 0.37
ATM Q13315 1/20 0.37
MAPT P10636 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
ALDH1A1 P00352 2/20 0.37
TP53 P04637 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
USP2 O75604 1/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NPC1 O15118 1/20 0.36
HSP90AA1 P07900 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313230 0.87 KMT2A (0.43) KMT2APOLBMEN1FAAHMGLL
SCHEMBL4318842 0.84 MGLL (0.42) KMT2APOLBMEN1MGLLALDH1A1
SCHEMBL4311381 0.83 POLB (0.39) POLBFAAHMGLLMAPTUSP2
SCHEMBL13667455 0.83 FAAH (0.47) KMT2APOLBMEN1FAAHSMN1; SMN2
SCHEMBL4306732 0.83 FAAH (0.47) KMT2APOLBMEN1FAAHSMN1; SMN2
SCHEMBL13667456 0.83 FAAH (0.47) KMT2APOLBMEN1FAAHSMN1; SMN2
SCHEMBL4312797 0.82 ALDH1A1 (0.40) KMT2AMEN1GFERATMMAPT
SCHEMBL4313590 0.82 POLB (0.37) KMT2APOLBMEN1L3MBTL1USP2
SCHEMBL4315951 0.81 POLB (0.37) POLBFAAHMGLL
SCHEMBL4309717 0.81 MGLL (0.46) KMT2AMEN1FAAHMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879873-B1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK BIOPHARMACEUTICALS CO LTD (KR) 2013-10-09 EP disclosed
US-7598279-B2 Neurotherapeutic azole compounds SK HOLDINGS CO., LTD. (KR) 2009-10-06 US disclosed
US-7598279-B2 Neurotherapeutic azole compounds SK HOLDINGS CO., LTD. (KR) 2009-10-06 US disclosed
EP-1879873-A1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK Holdings Co., Ltd. (KR) 2008-01-23 EP disclosed
US-20060258718-A1 Neurotherapeutic azole compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2006-11-16 US disclosed
WO-2006112685-A1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK HOLDINGS CO., LTD. (KR) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258718-A1 Neurotherapeutic azole compounds CHRNA10, CHRNA4, CHRNA3 KMT2A 1096/4885POLB 4187/4885DGAT1 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.